New study aims to treat deadly fungus in patients with liver issues
NCT ID NCT07337720
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called liposomal amphotericin B in 40 ICU patients who have a severe fungal infection (invasive aspergillosis) and liver problems. The drug is given daily for 2 weeks, followed by 4 weeks of monitoring. The goal is to see if it is safe and effective for this high-risk group, where treatment options are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- liposomal amphotericin B
- What this could lead to
- If successful, this could provide a safer treatment option for patients with severe fungal infections and liver problems, potentially reducing mortality.
- What could go wrong
- This is a small, early-stage study with only 40 participants and no control group, so results may not be conclusive. The drug may still cause liver or kidney side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASPERGILLOSIS INVASIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.